Home | My NASDAQ | Tools | Mobile | Company List | ETFs | Pre-Market Quotes Real-Time Quotes After Hours Quotes
Home > Quotes > GILD > Company News
GILD
GILD
$50.49
*
0.13
negative
0.26%

*Data as of May 25, 2012   | Gilead Sciences, Inc. | Industry: Health Care | HQ: California, United States
 
 

Symbol List ViewsSymbol List Views

Stock DetailsStock Details

Stock DetailsCHARTS

Stock DetailsCOMPANY NEWS

Stock DetailsSTOCK ANALYSIS

Stock DetailsFUNDAMENTALS

Stock DetailsHOLDINGS

Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.


Don't know the stock symbol? Use the symbol lookup tool.

Alphabetize the sort order of my symbols 
Symbol Lookup
Log in or Register
 Save stocks for next time
 |  Sponsored

GILD News Headlines

Share |


   


FDA Nod for Merck Drug Label Update - Analyst Blog
5/24/2012 6:44:13 PM - Zacks.com

Gilead Drug Up for European Review - Analyst Blog
5/24/2012 4:41:01 PM - Zacks.com

Gilead Sciences Says MAA For Cobicistat Validated By European Medicines Agency
5/23/2012 4:53:00 PM - RTT News

Gilead Sciences To Participate In BofA Merrill Lynch Conference At 6:40 PM ET
5/16/2012 3:03:00 PM - RTT News

The Zacks Analyst Blog Highlights: Gilead Sciences, Abbott Labs, Alliance Data Systems Corporation, Blue Nile and Bristol-Myers Squibb - Press Releases
5/15/2012 9:07:18 AM - Zacks.com

Good News for Gilead - Analyst Blog
5/14/2012 3:00:01 PM - Zacks.com

Syocks Selling Off Early; S&P 500 and Nasdaq Drop to 3-Month Lows
5/14/2012 10:32:00 AM - Knobias

A Health Care Fortnight for the Record Books
5/14/2012 7:00:00 AM - TheStreet

Gilead Sciences HIV Drug Quad Gets FDA Panel Backing
5/11/2012 4:56:00 PM - RTT News

Stocks Close Mixed and Post Second Consecutive Weekly Decline
5/11/2012 4:26:00 PM - Knobias

FDA Advisory Panel Oks Gilead's Once-Daily Quad Single Tablet Regimen For HIV
5/11/2012 3:49:00 PM - RTT News

UPDATE: FDA Panel Backs Gilead's HIV 'Quad' Medicine
5/11/2012 3:32:00 PM - Dow Jones Business News

FDA Panel Backs Gilead's HIV 'Quad' Medicine
5/11/2012 3:05:00 PM - Dow Jones Business News

Stocks Modestly Higher at Midday on Positive Data
5/11/2012 1:32:00 PM - Knobias

Stocks Turn Mixed After Jump in May Consumer Sentiment
5/11/2012 10:34:00 AM - Knobias

Markets Headed for Lower Open After JP Morgan Reveals $2 Billion in Trading Losses
5/11/2012 9:19:00 AM - Knobias

WSJ BLOG/Health: A.M. Vitals: Extended Breast Feeding, Obesity Drug and Heart Devices
5/11/2012 9:01:00 AM - Dow Jones Business News

Futures Weaker after JP Morgan Announces $2 Billion in Trading Losses
5/11/2012 8:16:00 AM - Knobias

FDA Panel Backs Approval Of Gilead's Truvada To Block HIV Infection
5/10/2012 9:04:00 PM - RTT News

Stocks Selling Off Early on European Fears
5/9/2012 10:35:00 AM - Knobias

WSJ BLOG/Health: A.M. Vitals: GSK's Hostile Human Genome Bid; Regulators Like Preventive HIV Drug
5/9/2012 9:18:00 AM - Dow Jones Business News

FDA: Safety Of Proposed Gilead HIV Drug "Generally Acceptable"
5/9/2012 8:32:00 AM - Dow Jones Business News

FDA Appears To Support Gilead HIV Drug As Prevention Tool
5/8/2012 11:44:00 AM - Dow Jones Business News

Gilead Sciences To Present At Deutsche Conference; Webcast At 10:40 AM ET
5/8/2012 9:40:00 AM - RTT News

Vertex Is the Next Gilead Sciences or Alexion
5/7/2012 4:06:00 PM - TheStreet